The stock of bluebird bio Inc (NASDAQ:BLUE) is a huge mover today! About 1.39 million shares traded hands or 2.96% up from the average. bluebird bio Inc (NASDAQ:BLUE) has risen 50.18% since March 8, 2016 and is uptrending. It has outperformed by 40.87% the S&P500.
The move comes after 7 months negative chart setup for the $2.76B company. It was reported on Oct, 11 by Barchart.com. We have $65.98 PT which if reached, will make NASDAQ:BLUE worth $165.60M less.
Analysts await bluebird bio Inc (NASDAQ:BLUE) to report earnings on November, 2. They expect $-1.48 EPS, down 25.42% or $0.30 from last year’s $-1.18 per share. After $-1.59 actual EPS reported by bluebird bio Inc for the previous quarter, Wall Street now forecasts -6.92% EPS growth.
bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage
Out of 13 analysts covering bluebird bio (NASDAQ:BLUE), 10 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 77% are positive. bluebird bio has been the topic of 26 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, November 18 by Goldman Sachs. Morgan Stanley initiated bluebird bio Inc (NASDAQ:BLUE) rating on Tuesday, September 8. Morgan Stanley has “Equal-Weight” rating and $143.0 price target. The stock of bluebird bio Inc (NASDAQ:BLUE) has “Buy” rating given on Monday, December 7 by Jefferies. The company was initiated on Friday, June 3 by Cantor Fitzgerald. The stock has “Buy” rating given by Zacks on Tuesday, August 11. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, December 17. The firm has “Buy” rating by Roth Capital given on Saturday, August 15. As per Monday, October 5, the company rating was upgraded by Morgan Stanley. Roth Capital maintained the stock with “Buy” rating in Friday, August 28 report. Jefferies initiated the stock with “Buy” rating in Friday, October 23 report.
According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.34, from 1.34 in 2016Q1. The ratio worsened, as 29 funds sold all bluebird bio Inc shares owned while 52 reduced positions. 20 funds bought stakes while 61 increased positions. They now own 42.29 million shares or 3.30% more from 40.94 million shares in 2016Q1.
The California-based Wells Fargo & Communications Mn has invested 0.01% in bluebird bio Inc (NASDAQ:BLUE). Spot Trading Llc holds 0% or 4,257 shares in its portfolio. Woodstock last reported 0.18% of its portfolio in the stock. Vident Advisory Limited Com last reported 0.1% of its portfolio in the stock. Cubist Systematic Strategies Ltd holds 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 290 shares. Grp Inc One Trading L P owns 26,695 shares or 0.01% of their US portfolio. Proshare Limited Liability accumulated 0.02% or 33,253 shares. Federated Investors Pa last reported 31,562 shares in the company. Sphera Funds Mngmt last reported 40,000 shares in the company. Wellington Grp Incorporated Llp accumulated 2.08M shares or 0.02% of the stock. Geode Cap Ltd Liability Corporation has 268,368 shares for 0.01% of their US portfolio. Planning Corporation accumulated 4,440 shares or 0.02% of the stock. Portolan Capital Mgmt Ltd holds 37,090 shares or 0.23% of its portfolio. Rhumbline Advisers holds 0.01% or 45,401 shares in its portfolio. Sandy Spring National Bank & Trust last reported 0% of its portfolio in the stock.
More news for bluebird bio Inc (NASDAQ:BLUE) were recently published by: Fool.com, which released: “Why bluebird bio Inc. Jumped Monday” on September 12, 2016. Fool.com‘s article titled: “Why bluebird bio Inc. Jumped Again Today” and published on September 15, 2016 is yet another important article.
BLUE Company Profile
bluebird bio, Inc., incorporated on April 16, 1992, is a biotechnology company. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. With its lentiviral gene therapies, T cell immunotherapy expertise and gene editing capabilities, it offers an integrated product platform with application in severe genetic and rare diseases, and in oncology. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. The Company’s oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. The Company’s oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.